A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody, Versus Investigator’s Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)

Project: Research

Project Details

StatusActive
Effective start/end date14/08/24 → 30/11/26

Keywords

  • clinical trial
  • Follicular Lymphoma
  • Odronextamab
  • haematological malignancy

Clinical Trial Phase

  • Phase III (a & b)